Taiho Pharmaceutical Co., Ltd. is engaged in the research
Taiho Pharmaceutical Co., Ltd. is engaged in the research, development, production, distribution, and marketing of pharmaceutical products. The company develops drugs primarily in the area of oncology. It also develops other pharmaceuticals, controlled medical devices, designated quasi-drugs, second-class OTC drugs, designated second-class OTC drugs, and third-class OTC drugs; S-1 for the treatment of gastric cancer; TAS-102 for the treatment of colorectal cancer; and anticancer agents for oncologists, other medical care professionals, and patients. In addition, it engages in the research and development in the areas of oncology,
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Feb 27, 2018
Quentis Therapeutics
|
Series A | $48M | Biotechnology | — |